Amylyx Pharmaceuticals, Inc. — Form 10-Q
Filed November 5, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Amylyx signed two manufacturing and supply agreements: (1) Bachem Americas for an unspecified active pharmaceutical ingredient with a June 2025 LOI providing guaranteed manufacturing slots and capacity commitment (details redacted); (2) PolyPeptide Group AG for Avexitide with an 8-year initial term, minimum annual quantities (redacted), tiered pricing from USD [***] per unit, and non-refundable pre-payments of USD 30 million capacity reservation plus Post-PPQ pre-payment (redacted). Both agreements govern long-term commercial supply with detailed quality, delivery, and termination provisions.
Why this rating
Dual CDMO partnerships are material for a $518M biotech; secure supply reduces regulatory risk. Pre-payments of $30M+ represent ~6% of market cap, substantial but typical for pharma manufacturing. Avexitide supply lock-in supports commercialization if approved, but approval status and pricing remain redacted.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-4.4% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $29.85 | +10 min · unknown $29.68 ▼ 0.55% | +30 min · unknown $29.34 ▼ 1.73% | +1 hr · unknown $29.52 ▼ 1.11% | +4 hrs · unknown $28.39 ▼ 4.91% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.